Novo Integrated Sciences Inc Stock Price, News & Analysis

Novo Integrated Sciences (NASDAQ: NVOS) announced that its subsidiary, Novo Healthnet Limited, received a Natural Product Number (NPN) from Health Canada for its IoNovo Iodide product. This marks the third iodine-based product to be approved, following IoNovo Iodine and IoNovo for Kids, which are all developed by Terragenx Inc., a fully owned subsidiary. Iodide is recognized for its contributions to healthy metabolism and cognitive function. The IoNovo line is available for purchase via the Terragenx e-commerce platform, highlighting Novo's commitment to innovative health solutions.

Novo Integrated Sciences (NASDAQ: NVOS) announced that its subsidiary, Novo Healthnet Limited, received a Natural Product Number (NPN) from Health Canada for its IoNovo for Kids pure iodine oral spray. This product is the first of its kind designed specifically for children under 13, ensuring safety and efficacy. Iodine is recognized for its health benefits, and this innovative oral spray provides a convenient way for parents to enhance their children's biosecurity. Novo continues to focus on developing health and wellness solutions through its multidisciplinary healthcare ecosystem.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) reported 47% revenue growth for the fiscal quarter ended November 30, 2021, reaching $3.16 million, attributed mainly to the Acenzia acquisition. Following a $15 million registered direct offering, the company aims to enhance its decentralized healthcare ecosystem. Anticipating 400% revenue growth and expanding internationally, Novo plans to launch NovoConnect by March 31, 2022. Despite an increase in operating costs and a net loss of $1.81 million, the company is confident about future integration benefits.

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) has signed an Amended and Restated Master Facility License Agreement with LA Fitness Canada effective December 15, 2021. This agreement aims to establish micro-clinics offering outpatient physical and occupational therapy services at LA Fitness locations in Canada, following a temporary closure due to COVID-19. Novo's CEO emphasized the commitment to patient-first health and wellness as a pivotal aspect of the company's business model, which includes decentralized healthcare delivery through service networks, technology, and personalized products.

Novo Integrated Sciences (NASDAQ:NVOS) announced that its subsidiary, Novo Healthnet Limited, received a Natural Product Number (NPN) from Health Canada for its IoNovo Iodine. This proprietary iodine micronutrient is delivered in an oral or nasal spray form, promoting high bioavailability. The product supports personal biosecurity and is recognized for its disinfectant properties. The recent acquisition of Terragenx Inc. enables its immediate commercialization. Novo emphasizes a holistic healthcare approach through integrated technology and multidisciplinary services.

Novo Integrated Sciences (NASDAQ:NVOS) reported its fiscal year results for 2021, highlighting an 18.4% revenue increase to $9.3 million, aided by easing COVID restrictions and Acenzia's contribution. The net loss decreased by 9.2% to $4.46 million due to higher revenues and gross profits. The company made significant investments in healthcare assets and technology, with plans to launch the NovoConnect app in early 2022. Cash and equivalents stood at $8.3 million, while total assets reached $61.9 million, indicating a solid financial foundation for future expansion.

Novo Integrated Sciences (NASDAQ:NVOS) has acquired a 91% stake in Terragenx and its intellectual property for a water-soluble iodine micro-nutrient, approved for over-the-counter and e-commerce distribution in the U.S. and Canada. The acquisition, valued at $3.35 per share, is expected to enhance Novo's multidisciplinary healthcare ecosystem. The iodine formulation is designed to be safely ingested, offering antibacterial and antiviral properties. CEO Robert Mattacchione emphasized the strategic importance of this acquisition for expanding their health and wellness product portfolio.

Novo Integrated Sciences (NASDAQ:NVOS) announced a joint venture with EK-Tech Solutions to establish MiTelemed+, enhancing telehealth capabilities through the iTelemed platform. This initiative aims to improve patient-practitioner interactions by integrating sophisticated diagnostic tools for remote evaluations. With a 50/50 profit-sharing arrangement, Novo Healthnet will commercialize the services globally. The venture responds to the growing demand for telemedicine and aims to decentralize healthcare delivery, making it more accessible and cost-effective, particularly post-pandemic.

Novo Integrated Sciences (NASDAQ:NVOS) announces that Chairman and CEO Robert Mattacchione will present at the Benzinga Virtual Global Healthcare Small Cap Conference on September 30, 2021, at 1:15 p.m. ET. The management team will also be available for one-on-one meetings during the event. Novo Integrated Sciences is committed to a patient-first approach in healthcare, focusing on decentralized services that integrate advanced medical technology.

For registration: Benzinga Conference.